To investigate the safety, efficacy and long-term complications of transurethral domestic 1 470 nm laser vaporization for the treatment of <30 g small-volume benign prostatic hyperplasia.

From October 2017 to September 2018, 45 patients with <30 g small benign prostatic hyperplasia were retrospectively studied, including 20 patients in the TURP group and 25 patients in the 1 470 nm laser group. The general clinical materials, perioperative complications and follow-up data of the two groups were recorded.

45 patients were operated successfully, the mean follow-up period was 12.6 months (9-16 months). There were no significant differences in age, prostate volume, IPSS, RUV, Qmax, and QOL baseline data between the two groups (P>0.05). The IPSS, RUV, Qmax and QOL of the two groups were improved compared with those before operation (P<0.05) and there was no significant difference between the two groups (P>0.05). The operation time of the 1 470 nm laser group [(48.6±13.6) min vs (56.8±11.7) min, P=0.038], bladder irrigation duration [(0.8±0.5) d vs (1.5±0.9) d, P=0.001], catheter indwelling time [(2.7±0.6) d vs (4.7±0.9) d, P<0.001] and hospital stay [(4.2±1.2) d vs (5.2±1.9) d, P=0.036] were significantly shorter than those in the TURP group, with less hemoglobin changes before and after surgery [(5.5±2.4) g/L vs (11.6 ±2.7) g/L, P<0.01]. Follow-up period revealed 2 cases of urethral stricture in the TURP group and no urethral stricture in the 1 470 nm laser group.

Transurethral domestic 1 470 nm laser vaporization is safe and effective for the treatment of <30 g small-volume benign prostatic hyperplasia, intraoperative bleeding is less and recovery time is shorter when compared with TURP, and no urethral stricture complication was discovered during the follow-up period, which can provide an individualized treatment method for BPH.